Subcutaneous · Amylin analog
Petrelintide
9 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
9
Ongoing
4
Recruiting
2
Completed
5
Sites
79
Countries
6
Endpoints
131
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
5
Phase 2
4
Trials by status
Not yet recruiting
1
Recruiting
2
Active, not recruiting
1
Completed
5
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
69
Glycemic / diabetes
21
Weight & body composition
18
Cardiometabolic biomarkers
17
Other (unclassified)
5
Other clinical outcomes
1
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
14
TmaxSafety/PK
10
CmaxSafety/PK
7
Body weight, % changeWeight
6
Treatment-emergent AEs (any)Safety/PK
6
Half-lifeSafety/PK
4
Body weight, absolute change (kg)Weight
3
Waist circumference, changeWeight
3
HbA1c, changeGlycemic
3
Fasting glucose, changeGlycemic
3
hs-CRP, changeBiomarker
3
Postprandial glucoseGlycemic
3
≥5% weight-loss respondersWeight
2
≥10% weight-loss respondersWeight
2
Immunogenicity (ADA)Safety/PK
2
Systolic BP, changeBiomarker
2
Diastolic BP, changeBiomarker
2
BMI, changeWeight
1
HDL-C, changeBiomarker
1
LDL-C, changeBiomarker
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
9 of 9
Showing 1-9 of 9 trials